Facioscapulohumeral Muscular Dystrophy: Update on Pathogenesis and Future Treatments
- 25 October 2018
- journal article
- review article
- Published by Elsevier BV in Neurotherapeutics
- Vol. 15 (4), 863-871
- https://doi.org/10.1007/s13311-018-00675-3
Abstract
No abstract availableKeywords
This publication has 81 references indexed in Scilit:
- Large scale genotype–phenotype analyses indicate that novel prognostic tools are required for families with facioscapulohumeral muscular dystrophyBrain, 2013
- Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2Nature Genetics, 2012
- DUX4 Activates Germline Genes, Retroelements, and Immune Mediators: Implications for Facioscapulohumeral DystrophyDevelopmental Cell, 2011
- Facioscapulohumeral Dystrophy: Incomplete Suppression of a Retrotransposed GenePLoS Genetics, 2010
- Clinical features of facioscapulohumeral muscular dystrophy 2Neurology, 2010
- Scapular fixation in muscular dystrophyCochrane Database of Systematic Reviews, 2010
- An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologiesThe EMBO Journal, 2008
- Specific Sequence Variations within the 4q35 Region Are Associated with Facioscapulohumeral Muscular DystrophyAmerican Journal of Human Genetics, 2007
- PILOT TRIAL OF DILTIAZEM IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHYNeurology, 2007
- Effects of training and albuterol on pain and fatigue in facioscapulohumeral muscular dystrophyZeitschrift für Neurologie, 2007